GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Avalo Therapeutics Inc
Avalo Therapeutics is a biotech company with a diversified portfolio of drug candidates. Its stock price reflects the risks and opportunities associated with each of its clinical projects. The chart is a history of successes and failures in drug development.
Share prices of companies in the market segment - Pharma immune
Avalo Therapeutics is a biopharmaceutical company focused on the treatment of inflammatory and immune diseases. We classify it in the Pharmaceuticals (Immunology) segment, as its developments are aimed at modulating the body's immune response. The graph below shows the dynamics of this complex and promising area of ββmedicine.
Broad Market Index - GURU.Markets
Avalo Therapeutics is a biopharmaceutical company developing drugs to treat inflammatory and immune diseases. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
AVTX - Daily change in the company's share price Avalo Therapeutics Inc
The volatility of Avalo Therapeutics, a biopharmaceutical company, is measured by change_co. It reflects sensitivity to clinical trial results. This metric is a key component of formulas on System.GURU.Markets for analyzing the high-risk biotech sector.
Daily change in the price of a set of shares in a market segment - Pharma immune
Avalo Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with AVTX's performance, which is dependent on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Avalo Therapeutics is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Avalo Therapeutics Inc
Avalo Therapeutics, Inc.'s year-over-year performance tells the story of its strategic pivot. Its 12-month market cap reflects its decision to focus on developing a single, highly promising drug for treating immune diseases. Its valuation is a bet that this focused approach will prove successful.
Annual dynamics of market capitalization of the market segment - Pharma immune
Avalo Therapeutics, Inc. is a clinical-stage biotech company focused on developing drugs for the treatment of inflammatory diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Avalo Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Avalo Therapeutics Inc
Avalo Therapeutics is a biotech company whose value is directly dependent on progress in clinical trials. Monthly fluctuations on the chart reflect investors' reactions to news, including the release of trial data, decisions to continue or terminate programs, and partnerships with major pharmaceutical companies.
Monthly dynamics of market capitalization of the market segment - Pharma immune
This chart reflects the dynamics of the volatile biotech sector. For Avalo, a clinical-stage company, it's the backdrop. Its movements show how successes and failures in clinical trials, as well as M&A activity, have impacted investor sentiment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Avalo Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat immune and inflammatory diseases. Its value is almost entirely dependent on the results of clinical trials. The broader market has little impact on Avalo's stock; its fate is decided in labs and clinics, which can lead to sharp movements counter to the market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Avalo Therapeutics Inc
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on treating inflammatory diseases. Its weekly stock price is volatile and dependent on news of clinical trial results, which could dramatically change its valuation.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Avalo Therapeutics is a biopharmaceutical company focused on immunology. Its stock, like many development-stage companies, reacts strongly to news about clinical trials. This chart clearly shows how lab data is creating a unique trajectory for the company, distinct from the broader pharmaceutical sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Avalo is a clinical-stage biotech. Its shares rely on trial news, not macroeconomics. The chart clearly demonstrates how the company's performance is disconnected from the stock market and follows its own scientific calendar.
Market capitalization of the company, segment and market as a whole
AVTX - Market capitalization of the company Avalo Therapeutics Inc
Avalo Therapeutics' market capitalization chart reflects a biotech company struggling to find its way after a series of setbacks. Its low valuation and volatility reflect its strategy of acquiring and developing new assets at an early stage. It's a high-risk bet that one of its new projects will be successful.
AVTX - Share of the company's market capitalization Avalo Therapeutics Inc within the market segment - Pharma immune
Avalo Therapeutics is a clinical-stage biotech focused on treating inflammatory and immune diseases. Its market share reflects the potential of its developments. Its market capitalization chart is a venture capital story, full of risks and hopes for the next scientific breakthrough in this complex field of medicine.
Market capitalization of the market segment - Pharma immune
The chart below shows the overall value of the biotech sector. Avalo Therapeutics is a company trying to find its niche by developing drugs to treat immune and inflammatory diseases. Its history, compared to the market, is full of strategic shifts. This exemplifies the difficulty of a small biotech company finding its path to success.
Market capitalization of all companies included in a broad market index - GURU.Markets
Avalo Therapeutics is a biopharmaceutical company focused on treating inflammatory and immunological diseases. Its market capitalization reflects the potential of its research and development. The chart below shows the economic weight of early-stage companies.
Book value capitalization of the company, segment and market as a whole
AVTX - Book value capitalization of the company Avalo Therapeutics Inc
Avalo's book value is the equity and intellectual property of its portfolio of drugs for treating immune and inflammatory diseases. The chart tells the story of a biotech company that, after a series of setbacks and restructuring, is attempting to rebuild its foundation, focusing on the most promising candidates in its portfolio.
AVTX - Share of the company's book capitalization Avalo Therapeutics Inc within the market segment - Pharma immune
Avalo Therapeutics treats inflammatory diseases. The chart shows its share of actual R&D assets. These include its laboratories and clinical programs, which provide the foundation for developing new therapeutic approaches.
Market segment balance sheet capitalization - Pharma immune
Avalo Therapeutics is a biotech company whose value is locked into its development pipeline. Its business is capital-light. The chart below reflects the capital intensity of the pharmaceutical sector, which highlights its R&D-focused model.
Book value of all companies included in the broad market index - GURU.Markets
Avalo Therapeutics is a biopharmaceutical company focused on immunology. Its assets are its clinical programs. A modest stake in BCap_All is a material resource the company is investing in the discovery of new treatments for inflammatory diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Avalo Therapeutics Inc
Avalo Therapeutics is a biopharmaceutical company. Its market capitalization is lower than its book value (primarily cash). This suggests the market is pessimistic about the success of its clinical programs.
Market to book capitalization ratio in a market segment - Pharma immune
Avalo Therapeutics is a biotech company focused on treating inflammatory diseases. Its value is driven by the potential of its pipeline drugs. This metric represents a significant premium to book value, reflecting investor expectations for the success of clinical trials.
Market to book capitalization ratio for the market as a whole
Avalo Therapeutics is a biotech company specializing in the treatment of inflammatory diseases. Its valuation depends almost entirely on the success of clinical trials. This chart demonstrates how market value in the biotech sector can be detached from book value, reflecting hopes for future drugs.
Debts of the company, segment and market as a whole
AVTX - Company debts Avalo Therapeutics Inc
Avalo Therapeutics, a biopharmaceutical company focused on treating inflammatory diseases, manages its capital to advance its pipeline of candidates. Its debt strategy is aimed at funding clinical trials, an expensive process necessary to evaluate the safety and efficacy of new treatments.
Market segment debts - Pharma immune
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on treating inflammatory and immune diseases. Funding in this area is critical for conducting expensive trials. This chart shows whether the company is pursuing the traditional biotech equity financing model.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Avalo Therapeutics Inc
Avalo Therapeutics is a biopharmaceutical company focused on treating inflammatory diseases. Clinical development requires significant financial investments over many years. This chart shows the company's reliance on debt capital, which is a direct indicator of its financial risk and the "margin of safety" it has to complete research.
Market segment debt to market segment book capitalization - Pharma immune
Avalo Therapeutics is a biotech company focused on treating inflammatory diseases. The chart shows debt trends in their sector. For a company in clinical trials, this allows them to assess how they are funding their research after strategic changes to their development pipeline and how this impacts their financial profile.
Debt to book value of all companies in the market
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on treating immune and inflammatory diseases. It is entirely equity-funded. This chart of the market's total debt load clearly demonstrates that Avalo's financial model is unlike any other traditional company. It's a high-risk, high-reward play.
P/E of the company, segment and market as a whole
P/E - Avalo Therapeutics Inc
Avalo Therapeutics is a biopharmaceutical company focused on the treatment of immune-inflammatory diseases. This chart shows that the company's valuation is based on the potential of its scientific developments. Investors analyze clinical trial data, betting on the development of new, effective treatments.
P/E of the market segment - Pharma immune
This industry chart for biotech companies serves as a benchmark for Avalo Therapeutics. It reflects overall speculative valuations in the sector. Comparisons with it help understand how the market views Avalo's pipeline of inflammatory disease treatments and whether it believes its clinical programs are successful.
P/E of the market as a whole
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on treating inflammatory and immunological diseases. Its value depends on the success of its R&D programs. This chart, which tracks overall biotech sentiment, serves as a barometer for Avalo's availability of capital to fund its costly research.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Avalo Therapeutics Inc
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on the treatment of immune and inflammatory diseases. This chart reflects speculative expectations for its pipeline of candidates. The valuation is dependent on clinical trial results and strategic decisions regarding development or partnerships for its most promising programs.
%20P%2FE%20Avalo%20Therapeutics%20Inc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Avalo-Therapeutics-Inc&v=1772667927105 "Chart of the company's future (projected) P/E Avalo Therapeutics Inc")
Future (projected) P/E of the market segment - Pharma immune
Avalo Therapeutics is a biopharmaceutical company focused on treating inflammatory and immune diseases. This chart reflects investor expectations for the company's profitability relative to the sector. It allows for an assessment of the market's perception of its pipeline and its strategy for developing drugs for niche indications.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772667927149 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Avalo Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of immune-inflammatory diseases. Against the backdrop of general market expectations, as illustrated by this chart, Avalo's business is driven by scientific advances. The success of its clinical trials and the potential of its molecules are the primary drivers of its valuation.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772667927156 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Avalo Therapeutics Inc
Avalo Therapeutics is a biotech company focused on treating inflammatory and immune diseases. This chart shows the company's financial performance during clinical trials.
Profit of companies in the market segment - Pharma immune
Avalo Therapeutics is a biopharmaceutical company specializing in the treatment of immune and inflammatory diseases. This chart shows profitability in the immunology sector. For AVTX, this reflects their search for new approaches to treating complex conditions. Their success depends on clinical trial results and their ability to bring their developments to market.
Overall market profit
Avalo Therapeutics is a clinical-stage biotech company focused on treating inflammatory diseases. Its valuation is based on the potential of its pipeline programs. General economic cycles reflected in this chart do not affect the scientific process or the likelihood of clinical trial success.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Avalo Therapeutics Inc
Avalo Therapeutics is a clinical-stage biotechnology company focused on the treatment of inflammatory and immunological diseases. The revenue projections presented here are speculative and depend on the success of its lead candidate, AVTX-002, in clinical trials.
%20profit%20of%20the%20company%20Avalo%20Therapeutics%20Inc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Avalo-Therapeutics-Inc&v=1772667927287 "Graph of future (projected) profit of the company Avalo Therapeutics Inc")
Future (predicted) profit of companies in the market segment - Pharma immune
Avalo Therapeutics is a biopharmaceutical company focused on treating immune and inflammatory diseases. The profit outlook for this sector depends on clinical trial results. This chart reflects analysts' collective confidence in the commercial success of new drugs for conditions such as atopic dermatitis and Crohn's disease.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772667927375 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on treating inflammatory diseases. Its future depends on the success of clinical trials. The market revenue forecasts presented here impact the availability of capital for the biotech sector, which is essential for funding R&D.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772667927409 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Avalo Therapeutics Inc
Avalo Therapeutics is a biotech company specializing in the treatment of immune and inflammatory diseases. This chart shows the speculative valuation typical for a company in clinical development. The valuation fluctuates based on news about trial results and the potential of its drug candidates.
P/S market segment - Pharma immune
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on treating inflammatory and immune diseases. The company is developing a pipeline of several candidates. This chart reflects the average revenue estimate for the sector, providing insight into investor expectations for Avalo's research.
P/S of the market as a whole
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on treating inflammatory and immune diseases. Its future depends on the success of clinical trials. This chart provides a general market backdrop for assessing investor sentiment toward high-risk but potentially breakthrough medical technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Avalo Therapeutics Inc
Avalo Therapeutics is a biopharmaceutical company focused on treating inflammatory and immune diseases. This chart shows how investors estimate the company's future revenue potential based on its clinical programs and development pipeline.
%20P%2FS%20Avalo%20Therapeutics%20Inc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Avalo-Therapeutics-Inc&v=1772667927553 "The graph of the company's future (projected) P/S Avalo Therapeutics Inc")
Future (projected) P/S of the market segment - Pharma immune
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on treating inflammatory and immune diseases. This chart reflects the market's assessment of its scientific pipeline and the potential of its drug candidates to address significant medical unmet needs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772667927596 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Avalo Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat immune and inflammatory diseases. Their future depends on the success of their trials. This market optimism is vital for AVTX. Access to capital for developing breakthrough, but expensive, treatments is only possible if investors have faith in the future.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772667927647 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Avalo Therapeutics Inc
Avalo Therapeutics is a clinical-stage biotechnology company focused on the treatment of immune and inflammatory diseases. The company currently has no approved products on the market. This timeline will reflect its ability to successfully complete clinical trials and commercialize its developments.
Sales of companies in the market segment - Pharma immune
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on the treatment of inflammatory and immunological diseases. Their pipeline includes several candidates at various stages of development. Currently, the company has no commercial revenue, and its value is determined by the potential of its scientific developments.
Overall market sales
Avalo Therapeutics is a biopharmaceutical company focused on treating inflammatory and immune diseases. Its strategy includes developing both proprietary and licensed drugs to address unmet medical needs. This total revenue chart includes the healthcare sector, where AVTX aims to offer new treatment options.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Avalo Therapeutics Inc
Avalo Therapeutics is a biopharmaceutical company developing drugs to treat immune and inflammatory diseases. This chart reflects analysts' speculative expectations regarding the success of its clinical programs and the potential for developing new treatments.
%20sales%20of%20the%20company%20Avalo%20Therapeutics%20Inc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Avalo-Therapeutics-Inc&v=1772667927947 "Schedule of future (projected) sales of the company Avalo Therapeutics Inc")
Future (projected) sales of companies in the market segment - Pharma immune
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on treating inflammatory and immunological diseases. This chart shows forecasts for the entire autoimmune disorder drug market. It reflects the significant need for new treatments that can help patients with a wide range of conditions.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772667927972 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Avalo Therapeutics, a biotech company focused on treating immune diseases, sees this chart as a reflection of investment appetite for biotech. The robust economic growth projected here provides the capital needed to develop and clinically test drugs for a wide range of inflammatory conditions.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772667928066 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Avalo Therapeutics Inc
Avalo Therapeutics is a biotech company focused on treating inflammatory diseases. Being in the clinical stage, it incurs significant R&D expenses. This chart illustrates its current financial model: investing in a research portfolio with the goal of developing new treatments and future commercialization.
Market segment marginality - Pharma immune
Avalo Therapeutics is a clinical-stage biotechnology company focused on the treatment of immunoinflammatory diseases. This chart reflects the potential of its pipeline. Future strong operating income will confirm the success of its drugs and their potential to help patients.
Market marginality as a whole
Avalo Therapeutics is a clinical-stage biotech company. Its value and future depend on the success of its immunology research. This total market return chart bears no relation to the world of clinical trials, scientific data, and regulatory decisions that determine Avalo's fate.
Employees in the company, segment and market as a whole
Number of employees in the company Avalo Therapeutics Inc
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on treating inflammatory and immune diseases. This graphic shows a small team leading clinical programs, aiming to develop new treatments for patients with unmet medical needs in the field of immunology.
Share of the company's employees Avalo Therapeutics Inc within the market segment - Pharma immune
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on treating inflammatory diseases. Its strategy involves acquiring and developing promising assets. This approach requires a small but highly experienced business development and clinical research team, as reflected in this chart.
Number of employees in the market segment - Pharma immune
Avalo Therapeutics is a biopharmaceutical company specializing in the treatment of immune-inflammatory diseases. This graphic shows a team of scientists and researchers working to discover new approaches to treating diseases caused by immune dysfunction, which affect millions of people worldwide.
Number of employees in the market as a whole
Avalo Therapeutics, Inc. is a biopharmaceutical company focused on treating inflammatory diseases. Their work requires significant funding for clinical trials. Overall economic stability, reflected by employment trends, is driving investment into the biotech sector, allowing Avalo to advance its promising programs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Avalo Therapeutics Inc (AVTX)
Avalo Therapeutics, Inc. is a clinical-stage biopharmaceutical company. This chart is a classic example of biotech. Their very high market capitalization per employee reflects not current performance but rather investors' faith in the potential of their scientific developments. This is a measure of the intellectual capital of a small team of scientists.
%20of%20the%20company%20Avalo%20Therapeutics%20Inc%20(AVTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Avalo-Therapeutics-Inc-AVTX&v=1772667928480 "Chart of market capitalization per employee (in thousands of dollars) of the company Avalo Therapeutics Inc (AVTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Avalo Therapeutics is a biopharmaceutical company focused on treating inflammatory diseases. Its market capitalization depends on the success of its clinical programs. This chart shows how investors value its research and development efforts per employee, an important metric for research-stage biotech companies.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772667928506 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Avalo Therapeutics is a biopharmaceutical company focused on treating immune and inflammatory diseases. For a clinical-stage biotech, this metric reflects investor expectations for its pipeline and demonstrates how the market perceives the scientific potential of its drug candidates.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772667928512 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Avalo Therapeutics Inc (AVTX)
Avalo Therapeutics is a clinical-stage biotech company focused on immunology. This graph is negative. The company consists of scientists engaged in R&D. There is no profit; all funds are spent on development and clinical trials, which, if successful, will generate future revenue.
%20Chart%20Avalo%20Therapeutics%20Inc%20(AVTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Avalo-Therapeutics-Inc-AVTX&v=1772667928539 "Company Profit Per Employee (in thousands of dollars) Chart Avalo Therapeutics Inc (AVTX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Avalo Therapeutics (AVTX) is a clinical-stage biotech focused on treating immune and inflammatory diseases, particularly atopic dermatitis. This chart represents an industry benchmark. For biotech R&D companies, it serves as a benchmark, demonstrating the potential profitability the sector aspires to achieve if their targeted therapies are successful.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772667928569 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Avalo Therapeutics (AVTX) is a clinical-stage biotech company focused on treating inflammatory and immune diseases. This is R&D. The chart shows the R&D investment (negative return) per scientist required to advance their drug candidates through clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772667928577 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Avalo Therapeutics Inc (AVTX)
Avalo Therapeutics is a clinical-stage biopharmaceutical company. This graph reflects the company's path from science to commercialization. Potentially high future revenue per employee will result from the successful commercialization of its drugs for immune and inflammatory diseases, which will translate investments into real profits.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Avalo-Therapeutics-Inc-AVTX&v=1772667928583 "Sales chart per company employee Avalo Therapeutics Inc (AVTX)")
Sales per employee in the market segment - Pharma immune
Avalo Therapeutics (AVTX) is a clinical-stage biotech focused on immunology. They have no commercial revenue. This chart reflects their R&D stage: their research staff is focused on research, resulting in zero revenue per employee compared to the industry average, which is dominated by blockbusters.
Sales per employee for the market as a whole
Avalo Therapeutics is a biotech company focused on treating autoimmune and inflammatory diseases. It's an R&D company. This graph will likely show zero or minimal revenue (from partnerships) as their research team is in the clinical trials phase.
Short shares by company, segment and market as a whole
Shares shorted by company Avalo Therapeutics Inc (AVTX)
Avalo Therapeutics (AVTX) is a clinical-stage biotech developing drugs to treat immune and inflammatory diseases. This chart shows bearish bets. The high short position reflects investor concerns following a series of clinical trial failures and doubts about the viability of the remaining programs in development.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Avalo-Therapeutics-Inc-AVTX&v=1772667928684 "Short Shares Chart for the Company Avalo Therapeutics Inc (AVTX)")
Shares shorted by market segment - Pharma immune
Avalo (AVTX) is a biotech company specializing in the treatment of inflammatory and autoimmune diseases. This chart demonstrates the general skepticism in the biotech sector. It summarizes bearish bets, reflecting investor concerns about the risks of clinical trials.
Shares shorted by the overall market
Avalo Therapeutics (AVTX) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing that AVTX will be unable to raise funds to continue R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Avalo Therapeutics Inc (AVTX)
Avalo Therapeutics is a clinical-stage biotech. Its shares are extremely sensitive to trial news. This chart can soar above 70 on positive R&D data, but this is at risk of a correction. Oversold territory (<30) often reflects setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Avalo-Therapeutics-Inc-AVTX&v=1772667928789 "RSI 14 indicator chart for the company's stock Avalo Therapeutics Inc (AVTX)")
RSI 14 Market Segment - Pharma immune
Avalo (AVTX) is a biotech company developing antibodies to treat immune and inflammatory diseases. The RSI_14_Seg for "Pharma-immune" shows whether the entire biotech segment is overheated. The chart helps us understand whether AVTX's volatility is a reaction to their trials or simply the general hype in the sector.
RSI 14 for the overall market
Avalo Therapeutics (AVTX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AVTX (Avalo Therapeutics Inc)
Avalo Therapeutics (AVTX) is a clinical-stage biotech focused on treating autoimmune and inflammatory diseases. This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of the company's scientific platform and early clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AVTX-Avalo-Therapeutics-Inc&v=1772667928971 "A chart showing analyst consensus forecasts for the expected stock price. AVTX (Avalo Therapeutics Inc)")
The difference between the consensus estimate and the actual stock price AVTX (Avalo Therapeutics Inc)
Avalo Therapeutics is a clinical-stage biotech focused on developing drugs to treat immune and inflammatory diseases. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their confidence in the company's early R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AVTX-Avalo-Therapeutics-Inc&v=1772667928987 "A chart showing the difference between the consensus forecast and the actual stock price. AVTX (Avalo Therapeutics Inc)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Avalo Therapeutics (AVTX) is a clinical-stage biotech developing drugs to treat immune and inflammatory diseases. This chart shows analysts' overall expectations for the immunotherapy sector. It reflects how confident experts are in the company's R&D pipeline following its recent restructuring.
Analysts' consensus forecast for the overall market share price
Avalo Therapeutics (AVTX) is a clinical-stage biotech focused on treating autoimmune and inflammatory diseases. It is a high-risk R&D company. This chart shows overall market sentiment. For Avalo, as an R&D startup, it's important to understand how the overall risk appetite (sentiment) impacts their ability to fund trials. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Avalo Therapeutics Inc
Avalo Therapeutics (AVTX) is a clinical-stage biotech focused on developing drugs for the treatment of autoimmune and inflammatory diseases. This chart is a pure indicator of faith in their science. It doesn't reflect revenue, but rather a speculative estimate of their R&D progress and clinical trial data.
AKIMA Market Segment Index - Pharma immune
Avalo Therapeutics is a clinical-stage biopharmaceutical company specializing in the treatment of inflammatory and immune diseases. This chart shows the average index for the immunopharmaceutical sector. It helps investors assess how Avalo's performance, with its risky but potentially disruptive portfolio, compares to the industry average.
The AKIM Index for the overall market
Avalo Therapeutics, a biotech company focused on treating immune-inflammatory diseases, acquired an anti-IL-1Ξ² drug for the treatment of hidradenitis suppurativa. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this overloaded story compares to overall economic trends.
